Servatus begins dosing in world-first microbiome-focused rheumatoid arthritis trial
Servatus Biopharmaceuticals Ltd director and CEO Wayne Finlayson gives Andrew Scott from Proactive a brief recap on the company which has two platforms,...
Source: proactiveinvestors.com.au